Photopheresis in Early-stage Mycosis Fungoides

Launched by COLUMBIA UNIVERSITY · Dec 23, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called photopheresis for patients with early-stage cutaneous T-cell lymphoma, specifically a type known as Mycosis Fungoides. Photopheresis is currently used for patients with more advanced disease, but researchers want to see if it can help those in earlier stages too. The goal is to find out if this therapy can improve their condition and lead to better health outcomes.

To be eligible for this trial, participants need to be adults over the age of 18 who have been diagnosed with early-stage Mycosis Fungoides and have certain measurable skin lesions. They should also be willing to stop other treatments for their condition during the trial. Participants can expect to receive photopheresis therapy and will need to follow specific guidelines, such as avoiding certain medications and sun exposure during the study. It's important to note that this trial is currently recruiting participants, so interested individuals should speak with their healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Who are male or female, over the age of 18 and \<40 kg body weight with adequate veins to provide intravenous access.
• • 2. Who are willing to adhere to the protocol and sign an Informed Patient Consent Document
• • 3. Must not be on any other investigational device/drug treatment.
• • 4. Who have the diagnosis of Mycosis Fungoides (MF) including a skin biopsy consistent with MF (atypical epidermotropic or folliculocentric T-cells) with appropriate staging as IA, IB or IIA: T1 or T2 (patches or plaques) with measurable lesions.
• • 5. With IA stage must demonstrate a minor blood abnormality by morphology/laboratory assessment.
• • 6. With IIA stage - clinically significant nodes (1.5 cm) must have lymph node biopsy showing dermatopathic nodes or no involvement.
• • 7. Must be willing and able to discontinue concomitant medications for MF. Subjects currently taking the following drugs must discontinue medication with the following wash out periods prior to enrollment in the trial: PUVA or UVB Therapy - 4 weeks, topical nitrogen mustard or other topical chemotherapy - 4 weeks, bexarotene capsules or other systemic biologic agent - 3 weeks washout, high dose topical steroids, topical retinoids or immunotherapy - 2 week washout with 1% topical hydrocortisone , oral steroids above 10 mg - 30 day washout, unless subject has Addison's Disease or adrenal insufficiency
• • 8. Who are refractory to at least one of the standard therapies used to treat Stage IA, IB or IIA CTCL such as oral steroids, high-dose topical steroids, topical nitrogen mustard, Bexarotene, PUVA therapy, electron beam radiation, biological response modifiers or oral methotrexate.
• • 9. Must be willing to abstain from therapeutic sunbathing, phototherapy, tanning beds, etc. for the duration of the study.
• Exclusion Criteria:
• • 1. Who have MF (T3 cutaneous tumors or T4 exfoliative erythroderma) Stage IIB - IVB
• • 2. Who are unable to tolerate extracorporeal volume loss i.e., severe cardiac disease/anemia
• • 3. With deterioration of renal function who have a serum creatinine level greater than 3.0 mg/dL.
• • 4. With lipemic plasma \>500 ng/dL, uncontrolled diabetes, history of liver damage (2.5 x normal alanine transaminase (ALT), aspartate aminotransferase (AST), porphyria, lupus, positive tests for human immunodeficiency virus (HIV) antibody, hepatitis C virus (HCV) antibody or Hepatitis B Surface Antigen, severe emotional, behavioral or psychiatric problems that, in the opinion of the investigator, would result in poor compliance with the treatment regimen, and idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen compounds, heparin, or citrate.
• • 5. On oral prednisone therapy or high potency topical steroids.
• • 6. Who are pregnant or nursing a child.